|
Bolis, G., Scarfone, G., Polverino, G., Raspagliesi, F., Tateo, S., Richiardi, G., . . . Presti, M. J. J. o. c. o. (2004). Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol., 22(4), 686-690. Chiang, Y.-C., Chen, C.-A., Chiang, C.-J., Hsu, T.-H., Lin, M.-C., You, S.-L., . . . Lai, M.-S. J. J. o. g. o. (2013). Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol, 24(4), 342-351. Chu, E., & DeVita Jr, V. T. (2018). Physicians'' Cancer Chemotherapy Drug Manual 2019: Jones & Bartlett Learning. Connelly, E., Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G., & Belinson, J. J. G. o. (1996). Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Journal of the National Cancer Institute, 62(2), 166-168. Du Bois, A., Lück, H.-J., Meier, W., Adams, H.-P., Mobus, V., Costa, S., . . . Schröder, W. J. J. o. t. N. C. I. (2003). A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute, 95(17), 1320-1329. Fauci, J. M., Whitworth, J. M., Schneider, K. E., Subramaniam, A., Zhang, B., Frederick, P. J., . . . Straughn, J. M., Jr. (2011). Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol, 122(3), 532-535. doi:10.1016/j.ygyno.2011.05.023 Gates, M. A., Rosner, B. A., Hecht, J. L., & Tworoger, S. S. J. A. j. o. e. (2009). Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol., 171(1), 45-53. Hanna, R. K., Poniewierski, M. S., Laskey, R. A., Lopez, M. A., Shafer, A., Van Le, L., . . . Secord, A. A. J. G. o. (2013). Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 129(1), 74-80. Hendrayana, T., Wilmer, A., Kurth, V., Schmidt-Wolf, I. G., & Jaehde, U. J. S. p. (2017). Anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application. Sci. Pharm., 85(1), 8. Herrinton, L. J., Stanford, J. L., Schwartz, S. M., & Weiss, N. S. (1994). Ovarian cancer incidence among Asian migrants to the United States and their descendants. JNCI: Journal of the National Cancer Institute, 86(17), 1336-1339. Huang, Y.-W., Kuo, C.-T., Stoner, K., Huang, T. H.-Y., & Wang, L.-S. (2011). An overview of epigenetics and chemoprevention. FEBS letters, 585(13), 2129-2136. International, C. O. N. G. J. L. (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360(9332), 505. Kauff, N. D., Mitra, N., Robson, M. E., Hurley, K. E., Chuai, S., Goldfrank, D., . . . Borgen, P. I. J. J. o. t. N. C. I. (2005). Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst., 97(18), 1382-1384. Kliewer, E. V., & Smith, K. R. (1995). Ovarian cancer mortality among immigrants in Australia and Canada. Cancer Epidemiology and Prevention Biomarkers, 4(5), 453-458. Liutkauskiene, S., Janciauskiene, R., Jureniene, K., Grizas, S., Malonyte, R., & Juozaityte, E. J. B. c. (2015). Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer, 15(1), 105. Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., . . . Small, J. M. J. J. o. C. O. (2000a). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol, 18(1), 106-106. Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., . . . Small, J. M. J. J. o. C. O. (2000b). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol., 18(1), 106-106. Nagel, C., Backes, F. J., Hade, E., Cohn, D., Eisenhauer, E., O''Malley, D. M., . . . Salani, R. J. G. o. (2012). Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol, 124(2), 221-224. Nayl, B., Durando, X., Pomel, C., Dubray, P., Mouret-Reynier, M., Le Bouedec, G., . . . Cure, H. J. J. o. C. O. (2009). Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer. Gynecologic Cancer, 27(15_suppl), e16535-e16535. Olawaiye, A. B., Java, J. J., Krivak, T. C., Friedlander, M., Mutch, D. G., Glaser, G., . . . Lee, R. B. J. G. o. (2018). Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 151(1), 18-23. Piccart, M., Bertelsen, K., Stuart, G., Cassidy, J., Mangioni, C., Simonsen, E., . . . Blom, R. J. I. J. o. G. C. (2003). Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer, 13, 144-148. Piccart, M. J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., . . . Blom, R. J. J. o. t. N. C. I. (2000). Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. GYNECOLOGIC ONCOLOGY, 92(9), 699-708. Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. Cancer biology & medicine, 14(1), 9. Salehi, F., Dunfield, L., Phillips, K. P., Krewski, D., Vanderhyden, B. C. J. J. o. T., & Environmental Health, P. B. (2008). Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev., 11(3-4), 301-321. Sandercock, J., Parmar, M., Torri, V., & Qian, W. J. B. j. o. c. (2002). First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. British Journal of Cancer, 87(8), 815. Seebacher, V., Reinthaller, A., Koelbl, H., Concin, N., Nehoda, R., & Polterauer, S. (2017). The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study. PLoS One, 12(1), e0169272. doi:10.1371/journal.pone.0169272 Teng, Z., Han, R., Huang, X., Zhou, J., Yang, J., Luo, P., & Wu, M. (2016). Increase of incidence and mortality of ovarian cancer during 2003–2012 in Jiangsu Province, China. Frontiers in public health, 4, 146. Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., . . . Siegel, R. L. (2018). Ovarian cancer statistics, 2018. CA Cancer J Clin, 68(4), 284-296. doi:10.3322/caac.21456 Tsilidis, K., Allen, N., Key, T., Dossus, L., Lukanova, A., Bakken, K., . . . Hansen, L. J. B. j. o. c. (2011). Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer., 105(9), 1436. Wei, K., Li, Y., Zheng, R., Zhang, S., Liang, Z., Cen, H., & Chen, W. (2015). Ovary cancer incidence and mortality in China, 2011. Chinese Journal of Cancer Research, 27(1), 38. Whiteman, D. C., Murphy, M. F., Cook, L. S., Cramer, D. W., Hartge, P., Marchbanks, P. A., . . . Risch, H. A. J. J. o. t. N. C. I. (2000). Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst., 92(14), 1172-1177.
|